THIOTHIXENE. THERAPEUTICS Brands Navane see index for additional brand names. Generic? Yes

Similar documents
TRIFLUOPERAZINE. THERAPEUTICS Brands Stelazine see index for additional brand names

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes

PERPHENAZINE. THERAPEUTICS Brands Trilafon see index for additional brand names. Generic? Yes

LOXAPINE. THERAPEUTICS Brands Loxitane Adasuve (Staccato loxapine, inhaled loxapine) see index for additional brand names. Generic?

BLONANSERIN. THERAPEUTICS Brands Lonasen see index for additional brand names

CHLORPROMAZINE. THERAPEUTICS Brands Thorazine see index for additional brand names

ASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names

CYAMEMAZINE. THERAPEUTICS Brands Tercian see index for additional brand names

LURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names

ILOPERIDONE. THERAPEUTICS Brands FANAPT see index for additional brand names. Generic? No

PALIPERIDONE. THERAPEUTICS Brands INVEGA INVEGA SUSTENNA INVEGA TRINZA see index for additional brand names

AMISULPRIDE. THERAPEUTICS Brands Solian see index for additional brand names. Generic? No

QUETIAPINE. THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names. Generic? Yes

ZIPRASIDONE. THERAPEUTICS Brands Geodon see index for additional brand names

Medication Audit Checklist- Antipsychotics - Atypical

ARIPIPRAZOLE. THERAPEUTICS Brands Abilify Abilify Maintena Aristada see index for additional brand names. Generic? Yes

CHLORDIAZEPOXIDE. THERAPEUTICS Brands Limbitrol Librium Librax see index for additional brand names. Generic? Yes

TIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes

LOFLAZEPATE. THERAPEUTICS Brands Meilax see index for additional brand names. Generic? No. Class Benzodiazepine (anxiolytic)

LORAZEPAM. THERAPEUTICS Brands Ativan see index for additional brand names. Generic? Yes

CLOZAPINE. Generic? Yes

DIAZEPAM. THERAPEUTICS Brands Valium Diastat see index for additional brand names

OLANZAPINE tablets USP, for oral use OLANZAPINE orally disintegrating tablets USP, for oral use Initial U.S. Approval: 1996

Dosing & Administration

GALANTAMINE. THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names

CLONAZEPAM. THERAPEUTICS Brands Klonopin see index for additional brand names. Generic? Yes

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

AGOMELATINE. THERAPEUTICS Brands Valdoxan see index for additional brand names

ANTIPSYCHOTICS AGENTS CONVENTIONAL

GABAPENTIN. THERAPEUTICS Brands Neurontin see index for additional brand names

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

ATOMOXETINE. THERAPEUTICS Brands Strattera see index for additional brand names. Generic? Yes

TOPIRAMATE. THERAPEUTICS Brands Topamax Epitomax Topamac Topimax Trokendi XR Qsymia see index for additional brand names

Chapter 161 Antipsychotics

Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics

DOTHIEPIN. THERAPEUTICS Brands Prothiaden see index for additional brand names

OXCARBAZEPINE. THERAPEUTICS Brands Trileptal see index for additional brand names. Generic? Yes

ALPRAZOLAM. THERAPEUTICS Brands Xanax, Xanax XR see index for additional brand names. Generic? Yes

REBOXETINE. THERAPEUTICS Brands Norebox Edronax see index for additional brand names. Generic? No

ATOMOXETINE. THERAPEUTICS Brands Strattera see index for additional brand names. Generic? Yes

Elements for a Public Summary

Maximum Dose 30. mg/day. mg/day. mg/day. mg/day. 30 mg /day. mg/day. 15 mg /day 10. mg/day. mg/day

FULL PRESCRIBING INFORMATION: CONTENTS*

STARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.

ARIPIPRAZOLE tablets, for oral use Initial U.S. Approval: 2002

Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)

BUPROPION. THERAPEUTICS Brands Wellbutrin, Wellbutrin SR, Wellbutrin XL Zyban Aplenzin

PRESCRIBING GUIDELINES

LITHIUM. Generic? Yes

SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS

Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.5, 7.1).

Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of LATUDA (2.6, 7.1).

RISPERIDONE Tablets, USP, for oral use. Initial U.S. Approval: 1993

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia

Pharmacotherapy of psychosis and schizophrenia in youth

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology

Participating Hospital Certification Form

be administered three times daily.

NORTRIPTYLINE. THERAPEUTICS Brands Pamelor see index for additional brand names

Mellaril (thioridazine)

HIGHLIGHTS OF PRESCRIBING INFORMATION

CLOMIPRAMINE. THERAPEUTICS Brands Anafranil see index for additional brand names. Generic? Yes

The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in

Antipsychotics. Neuroleptics/ Major Tranquilizers. Hiwa K. Saaed, PhD Pharmacology & Toxicology /5/18 1

Navane. Inert ingredients for the intramuscular for injection formulation are: water; mannitol.

Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)

Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych

Maximum Dose. 10 mg. twice daily. 10 mg. sublingually. twice daily. 10 mg. sublingually. twice daily. 10 mg. twice daily. 10 mg.

Page 1 of RECENT MAJOR CHANGES Warnings and Precautions, Falls (5.

srmp DK/H/2440/ /DC aripiprazole

RISPERDAL (risperidone)

What Team Members Other Than Prescribers Need To Know About Antipsychotics

LITHIUM. Generic? Yes

Asenapine GENERAL INFORMATION DOSING INFORMATION. Available in generic

NAVANE Thiothixene Capsules Thiothixene Hydrochloride Concentrate

ADVERSE REACTIONS

Quetiapine Fumarate Tablets

BUPRENORPHINE. THERAPEUTICS Brands Suboxone (with naloxone) Probuphine (implant) see index for additional brand names

RECENT MAJOR CHANGES Warnings and Precautions:

Maximum Dose 10 mg. twice daily. 10 mg. twice daily. 10 mg. sublingually. twice daily. 10 mg. twice daily. 10 mg. twice daily

ZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide

Extrapyramidal Symptoms Associated with Antipsychotic Use

ACAMPROSATE. THERAPEUTICS Brands Campral see index for additional brand names. Tests None for healthy individuals. Generic? Not in U.S.

Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts

in the formulation. (4)

A Treatment for Acute Manic or Mixed Episodes of Bipolar I Disorder in Adults

CLOZAPINE. Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent.

New Medications in Early Psychosis

LOFEPRAMINE. THERAPEUTICS Brands Deprimyl Gamanil see index for additional brand names

Reference ID:

Antipsychotic Use in the Elderly

IMIPRAMINE. THERAPEUTICS Brands Tofranil see index for additional brand names

Quetiapine (SEROQUEL XR), extended-release tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg

RISPERDAL. (risperidone)

Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM

CLONIDINE. THERAPEUTICS Brands Duraclon (injection) Catapres Kapvay see index for additional brand names

CIZOREST Tablets (Amisulpride)

Transcription:

THIOTHIXENE THERAPEUTICS Brands Navane see index for additional brand names Generic? Yes Class Conventional antipsychotic (neuroleptic, thioxanthene, dopamine 2 antagonist) Commonly Prescribed for (bold for FDA approved) Schizophrenia Other psychotic disorders Bipolar disorder How the Drug Works Blocks dopamine 2 receptors, reducing positive symptoms of psychosis How Long Until It Works Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior If It Works Most often reduces positive symptoms in schizophrenia but does not eliminate them Most schizophrenic patients do not have a total remission of symptoms but rather a reduction of symptoms by about a third Continue treatment in schizophrenia until reaching a plateau of improvement After reaching a satisfactory plateau, continue treatment for at least a year after fi rst episode of psychosis in schizophrenia For second and subsequent episodes of psychosis in schizophrenia, treatment may need to be indefi nite Reduces symptoms of acute psychotic mania but not proven as a mood stabilizer or as an effective maintenance treatment in bipolar disorder After reducing acute psychotic symptoms in mania, switch to a mood stabilizer and/ or an atypical antipsychotic for mood stabilization and maintenance If It Doesn t Work Consider trying one of the fi rst-line atypical antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, amisulpride, asenapine, iloperidone, lurasidone) Consider trying another conventional antipsychotic If 2 or more antipsychotic monotherapies do not work, consider clozapine Best Augmenting Combos for Partial Response or Treatment Resistance Augmentation of conventional antipsychotics has not been systematically studied Addition of a mood-stabilizing anticonvulsant such as valproate, carbamazepine, or lamotrigine may be helpful in both schizophrenia and bipolar mania Augmentation with lithium in bipolar mania may be helpful Addition of a benzodiazepine, especially short-term for agitation Tests Since conventional antipsychotics are frequently associated with weight gain, before starting treatment, weigh all patients and determine if the patient is already overweight (BMI 25.0 29.9) or obese (BMI 30) Before giving a drug that can cause weight gain to an overweight or obese patient, consider determining whether the patient already has pre-diabetes (fasting plasma glucose 100 125 mg/dl), diabetes (fasting plasma glucose >126 mg/dl), or dyslipidemia (increased total cholesterol, LDL cholesterol, and triglycerides; decreased HDL cholesterol), and treat or refer such patients for treatment, including nutrition and weight management, physical activity counseling, smoking cessation, and medical management Monitor weight and BMI during treatment Consider monitoring fasting triglycerides monthly for several months in patients at high risk for metabolic complications and when initiating or switching antipsychotics While giving a drug to a patient who has gained >5% of initial weight, consider evaluating for the presence of pre-diabetes, diabetes, or dyslipidemia, or consider switching to a different antipsychotic Monitoring elevated prolactin levels of dubious clinical benefi t Patients with low white blood cell count (WBC) or history of drug-induced 713

THIOTHIXENE (continued) leucopenia/neutropenia should have complete blood count (CBC) monitored frequently during the fi rst few months and thiothixene should be discontinued at the fi rst sign of decline of WBC in the absence of other causative factors SIDE EFFECTS How Drug Causes Side Effects By blocking dopamine 2 receptors in the striatum, it can cause motor side effects By blocking dopamine 2 receptors in the pituitary, it can cause elevations in prolactin By blocking dopamine 2 receptors excessively in the mesocortical and mesolimbic dopamine pathways, especially at high doses, it can cause worsening of negative and cognitive symptoms (neuroleptic-induced defi cit syndrome) Anticholinergic actions may cause sedation, blurred vision, constipation, dry mouth Antihistaminic actions may cause sedation, weight gain By blocking alpha 1 adrenergic receptors, it can cause dizziness, sedation, and hypotension Mechanism of weight gain and any possible increased incidence of diabetes or dyslipidemia with conventional antipsychotics is unknown Notable Side Effects Neuroleptic-induced defi cit syndrome Akathisia Extrapyramidal symptoms, parkinsonism, tardive dyskinesia Galactorrhea, amenorrhea Sedation Dry mouth, constipation, vision disturbance, urninary retention Hypotension, tachycardia Rare fi ne lenticular pigmentation Life-Threatening or Dangerous Side Effects Rare neuroleptic malignant syndrome Rare seizures Rare blood dyscrasias Rare hepatic toxicity Increased risk of death and cerebrovascular events in elderly patients with dementiarelated psychosis Weight Gain Reported but not expected Sedation Occurs in signifi cant minority What to Do About Side Effects For motor symptoms, add an anticholinergic agent For sedation, take at night Reduce the dose Switch to an atypical antipsychotic Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia Best Augmenting Agents for Side Effects Benztropine or trihexyphenidyl for motor side effects Sometimes amantadine can be helpful for motor side effects Benzodiazepines may be helpful for akathisia Many side effects cannot be improved with an augmenting agent DOSING AND USE Usual Dosage Range 15 30 mg/day Dosage Forms Capsule 2 mg, 5 mg, 10 mg How To Dose Initial 5 10 mg/day; maximum dose generally 60 mg/day; higher doses may be given in divided doses Dosing Tips When thiothixene is dosed too high, it can induce or worsen negative symptoms of schizophrenia 714

(continued) THIOTHIXENE Lower doses may provide the best benefi t with fewest side effects in patients who respond to low doses Treatment should be suspended if absolute neutrophil count falls below 1,000/mm 3 Overdose Muscle twitching, sedation, dizziness, CNS depression, rigidity, weakness, torticollis, dysphagia, hypotension, coma Long-Term Use Some side effects may be irreversible (e.g., tardive dyskinesia) Habit Forming No How to Stop Slow down-titration (over 6 8 weeks), especially when simultaneously beginning a new antipsychotic while switching (i.e., cross-titration) Rapid discontinuation may lead to rebound psychosis and worsening of symptoms If antiparkinson agents are being used, they should be continued for a few weeks after thiothixene is discontinued Pharmacokinetics Initial elimination half-life approximately 3.4 hours Terminal elimination half-life approximately 34 hours Drug Interactions Respiratory depression may occur when thiothixene is combined with lorazepam Additive effects may occur if used with CNS depressants May decrease the effects of levodopa, dopamine agonists Some patients taking a neuroleptic and lithium have developed an encephalopathic syndrome similar to neuroleptic malignant syndrome Combined use with epinephrine may lower blood pressure May increase the effects of antihypertensive drugs except for guanethidine, whose antihypertensive actions thiothixene may antagonize Other Warnings/ Precautions If signs of neuroleptic malignant syndrome develop, treatment should be immediately discontinued Use cautiously in patients with alcohol withdrawal or convulsive disorders because of possible lowering of seizure threshold Antiemetic effect can mask signs of other disorders or overdose Do not use epinephrine in event of overdose, as interaction with some pressor agents may lower blood pressure Use cautiously in patients with glaucoma, urinary retention Observe for signs of ocular toxicity (pigmentary retinopathy, lenticular pigmentation) Avoid extreme heat exposure Use only with caution if at all in Parkinson s disease or Lewy body dementia Do Not Use If patient has CNS depression, is in a comatose state, has circulatory collapse, or there is presence of blood dyscrasias If there is a proven allergy to thiothixene SPECIAL POPULATIONS Renal Impairment Use with caution Hepatic Impairment Use with caution Cardiac Impairment Thiothixene may cause or aggravate EKG changes Elderly Some patients may tolerate lower doses better Although conventional antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with dementia-related psychosis Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events 715

THIOTHIXENE (continued) Children and Adolescents Safety and effi cacy have not been established in children under age 12 Generally consider second-line after atypical antipsychotics Potential Disadvantages Patients with tardive dyskinesia Children Elderly Primary Target Symptoms Positive symptoms of psychosis Negative symptoms of psychosis Pregnancy Controlled studies have not been conducted in pregnant women There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe diffi culty breathing, and diffi culty feeding Reports of extrapyramidal symptoms, jaundice, hyperrefl exia, hyporefl exia in infants whose mothers took a phenothiazine during pregnancy Psychotic symptoms may worsen during pregnancy and some form of treatment may be necessary Atypical antipsychotics may be preferable to conventional antipsychotics or anticonvulsant mood stabilizers if treatment is required during pregnancy Thiothixene should generally not be used during the fi rst trimester Thiothixene should be used during pregnancy only if clearly needed Breast Feeding Unknown if thiothixene is secreted in human breast milk, but all psychotropics assumed to be secreted in breast milk Recommended either to discontinue drug or bottle feed THE ART OF PSYCHOPHARMACOLOGY Potential Advantages For patients who do not respond to other antipsychotics Pearls Although not systematically studied, may cause less weight gain than other antipsychotics Conventional antipsychotics are less expensive than atypical antipsychotics Patients have very similar antipsychotic responses to any conventional antipsychotic, which is different from atypical antipsychotics where antipsychotic responses of individual patients can occasionally vary greatly from one atypical antipsychotic to another Patients with inadequate responses to atypical antipsychotics may benefi t from a trial of augmentation with a conventional antipsychotic such as thiothixene or from switching to a conventional antipsychotic such as thiothixene However, long-term polypharmacy with a combination of a conventional antipsychotic such as thiothixene with an atypical antipsychotic may combine their side effects without clearly augmenting the effi cacy of either For treatment-resistant patients, especially those with impulsivity, aggression, violence, and self-harm, long-term polypharmacy with 2 atypical antipsychotics or with 1 atypical antipsychotic and 1 conventional antipsychotic may be useful or even necessary while closely monitoring In such cases, it may be benefi cial to combine 1 depot antipsychotic with 1 oral antipsychotic Although a frequent practice by some prescribers, adding 2 conventional antipsychotics together has little rationale and may reduce tolerability without clearly enhancing effi cacy 716

(continued) THIOTHIXENE Suggested Reading Huang CC, Gerhardstein RP, Kim DY, Hollister L. Treatment-resistant schizophrenia: controlled study of moderate- and high-dose thiothixene. Int Clin Psychopharmacol 1987 ;2 :69 75. Sterlin C, Ban TA, Jarrold L. The place of thiothixene among the thioxanthenes. Curr Ther Res Clin Exp 1972 ;14 :205 14. 717